RUA Life Sciences (GB:RUA) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
RUA Life Sciences reports a robust first-half revenue growth, doubling from last year, driven by increased biomaterials royalties and contract manufacturing revenues. The group’s strategic acquisition of Abiss Group has bolstered its financial standing, with a pre-tax profit of £0.4 million, a significant recovery from a loss last year. The company is also adjusting its accounting year to align better with business planning.
For further insights into GB:RUA stock, check out TipRanks’ Stock Analysis page.
